A recent conversation among a group of physicians gave me a fair amount of distress and discomfort. The topic was an unproven treatment for COVID-19, the discomfort was the disinformation—in my opinion—being shared, and the distress was the fact that the discussion likely reflected what some doctors are actually doing for the treatment of patients who are infected with the corona virus. Evidence was left at the doorstep. As I reflected on the conversation I realized it was not unlike what I have experienced over decades as a medical oncologist, especially in years past where there was literally very little… Read More »Unproven Treatments in COVID-19: Why Do They Persist?
This may be one of the most important advances in cancer treatment this year, and almost no one in the major media has reported it, as best I can tell: Osimertinib (trade name Tagrisso™) made a huge difference in outcomes for patients with early stage EGFR-biomarker positive lung cancer when used as adjuvant (preventive) therapy after primary treatment (complete surgical resection in all patients; adjuvant chemotherapy in some). When I say huge, I mean huge: EGFR+ patients with stage IB to IIIC non-small cell lung cancer (the most common type of lung cancer) had a close to 90% survival at… Read More »A Major Advance In Lung Cancer Treatment: Does Anyone Know About It?